MelanA Recombinant Rabbit monoclonal Antibody IgG
Fig1: Western blot analysis of MelanA on different lysates using anti-MelanA antibody at 1/1,000 dilution.
Lane 1: Melanoma
Lane 2: B16-F1
Fig2: Flow cytometric analysis of B16-F1 cells with MelanA antibody at 1/50 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black). Alexa Fluor 488-conjugated goat anti rabbit IgG was used as the seconda antibody
Host Species; Species ReactivityRabbit; Human
Application SummaryWB, IHC, FC
Purification; FormulationProA affinity purified; 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide.; Liquid form.
ALTnamesMelanoma antigen recognized by T-cells 1, Antigen LB39-AA, Antigen SK29-AA, Protein Melan-A
BackgroundMelanoma-associated antigens recognized by cytotoxic T lymphocytes (CTL) have been grouped into three categories: melanocyte differentiation antigens, cancer/testis-specific antigens and mutated or aberrantly expressed antigens. Many of these antigens consist of peptides that are presented to T cells by HLA molecules; they represent potential targets for cancer immunotherapy. Melan-A (also designated MART-1) is a melanocyte differentiation antigen that is specific to melanomas, melanocyte cell lines and retina. Melan-A peptide is recognized by most HLA-A2-restricted tumor-specific tumor-infiltrating lymphocytes in patients with melanoma. Antimelanoma cytotoxic T lymphocytes can be generated with a Melan-A peptide, implicating Melan-A as a potential candidate for antigen-specific immunotherapy in melanoma patients.(ET1610-47)